TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2023
Historique:
received: 13 03 2023
revised: 23 03 2023
accepted: 24 03 2023
medline: 27 4 2023
pubmed: 25 4 2023
entrez: 25 4 2023
Statut: ppublish

Résumé

Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear.
MATERIALS AND METHODS METHODS
TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied.
RESULTS RESULTS
TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs.
CONCLUSION CONCLUSIONS
TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach.

Identifiants

pubmed: 37097685
pii: 43/5/1985
doi: 10.21873/anticanres.16359
doi:

Substances chimiques

12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine 0
Naphthoquinones 0
NF-kappa B 0
STAT3 protein, human 0
TLR4 protein, human 0
Antineoplastic Agents, Phytogenic 0
MMP2 protein, human EC 3.4.24.24
PTGS2 protein, human EC 1.14.99.1
VEGFA protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1985-1992

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Shuhai Chen (S)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Yuji Morine (Y)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan ymorine@tokushima-u.ac.jp.

Y U Saito (YU)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Shinichiro Yamada (S)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Hiroki Teraoku (H)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Tetsuya Ikemoto (T)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Mitsuo Shimada (M)

Department of Surgery, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH